Skip to main content
Log in

Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis

  • CASE REPORT
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The use of intravenous immunoglobulin (IVIg) has been reported as an immunomodulating agent in several autoimmune diseases, including systemic lupus erythematosus (SLE). Herein we report a SLE patient with severe clinical presentation that included pericarditis, pleural effusion, nephrotic range proteinuria, leukopenia, and lymphopenia. The patient received one course of high-dose IVIg (2.8 g/kg body weight), and within a week of post-IVIg therapy, her condition significantly improved. One-month post-IVIg there were decreased proteinuria, elevated leukocytes and lymphocytes count, decrease in antinuclear and anti-dsDNA antibodies, and disappearance of pericarditis and pleuritis. This case demonstrates the efficacy of IVIg in severe SLE with various clinical manifestations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 14 January 2000 / Accepted: 20 March 2000

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meissner, M., Sherer, Y., Levy, Y. et al. Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatology International 19, 199–201 (2000). https://doi.org/10.1007/s002960000053

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002960000053

Navigation